Indication
Gastroenteropancreatic Neuroendocrine Tumor Disease
1 clinical trial
5 products
Product
RYZ101Clinical trial
Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA TherapyStatus: Active (not recruiting), Estimated PCD: 2025-07-01
Product
EverolimusProduct
LanreotideProduct
SunitinibProduct
Octreotide LAR